Cecile geuijen

Company: Merus Therapeutics

Job title: Chief Scientific Officer

Seminars:

Zenocutuzumab, a HER2xHER3 Biclonics® Antibody That Can Overcome HER3 Mediated NRG1 Signaling In Tumor Cells By Docking On HER2 9:00 am

Uncovering Merus’ bispecific antibody screening platform to identify novel Biclonics and Triclonics antibodies Detection of NRG1 fusions & therapeutic targeting of NRG1 fusion positive patients, a biomarker-driven rare entity (with a significant unmet medical need) Zenocutuzumab shows Robust and Durable Responses in NRG1+ CancerRead more

day: Day Two